Our mission is to develop C-reactive protein (CRP) (Az121) and an anti-inflammatory derivative of CRP (Az175) for the prevention and reversal of nephritis in patients with systemic lupus erythematosus (SLE). The anti-inflammatory mutant of CRP has FcγR specificity that predicts more selective anti-inflammatory activity than that of natural sequence CRP.

Azano has an exclusive, worldwide license to two issued patents and five patent applications from a long term investigational program led by Terry Du Clos, MD, PhD and Carolyn Mold, PhD at the University of New Mexico Health Sciences Center and the Department of Veterans Affairs Medical Center, Albuquerque. Drs. Du Clos and Mold have demonstrated dramatic prevention and reversal of proteinuria in mouse models of SLE. In addition, they have shown that administration of CRP or CRP-treated macrophages reduces the degree of thrombocytopenia in a mouse model of human immune thrombocytopenia(ITP).

About Us
Azano Pharmaceuticals was founded by Puente Partners, LLC a venture development company in Albuquerque. John MacDonald, PhD, formerly Senior Vice President of R&D for MGI Pharma (acquired by Eisai Pharmaceuticals in 2008) and Meghan Norvell, PhD, MBA are Scientific Advisors for Azano. Loraine V. Upham, (former CEO and COO of CureDM, Inc.) has recently joined the team to spearhead preclinical development and partnership opportunities.